Xeptiva Therapeutics raises a $2.5M seed round

Xeptiva Ther­a­peu­tics is pleased to announce the suc­cess­ful closure of a $2.5 million seed funding round, led by Zen­tynel Fron­tier Invest­ments, with par­tic­i­pa­tion from iThink VC, ND Latam, Sergio Fogel, FEN Ven­tures and Uruguay Biotech Ven­tures. This funding will enable Xeptiva to advance its mission of rev­o­lu­tion­iz­ing pet health­care through inno­va­tive ther­a­peu­tic vac­cines tar­get­ing chronic con­di­tions.

With a focus on improv­ing the quality of life and extend­ing the life­span of animals, Xeptiva is devel­op­ing two key prod­ucts: a therapy for chronic osteoarthri­tis pain and another for atopic der­mati­tis in dogs, both cur­rently in clin­i­cal trial phases.

Xeptiva is tar­get­ing a sig­nif­i­cant market, esti­mated at $5 billion, address­ing the most preva­lent chronic con­di­tions in pets. Our approach offers a viable alter­na­tive to exist­ing treat­ments, which are often costly and limited in their effec­tive­ness.

The fundrais­ing comes at a crucial time for the company, which has achieved sig­nif­i­cant mile­stones, includ­ing the pro­duc­tion of its first batch of Xep01, its osteoarthri­tis treat­ment, and the com­ple­tion of pilot studies for its key devel­op­ing prod­ucts. This brings us closer to market readi­ness.

The support from our investors reflects their con­fi­dence in our mission and the dis­rup­tive poten­tial of our solu­tions in the animal health sector.

Xeptiva is on track to com­plete clin­i­cal trials and aims to secure reg­u­la­tory approval for its prod­ucts in 2026. As the pet care market con­tin­ues to grow, we are com­mit­ted to being pio­neers in the next gen­er­a­tion of vet­eri­nary ther­a­peu­tics.